SCILEX HOLDING CO

SCLXNASDAQ

🏆 #4567 by market capEarnings Dec 2US Equity

$543.28▲ $37.65 (+6.93%)

Simulated price

🔔

Track SCLX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 6.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$37M

Small Cap

📈Revenue Growth (YoY)

-46.5%

Declining

📊Gross Margin

41.5%

Healthy

💵FCF Margin

-56.7%

Thin

⚖️P/S Ratio

1.2x

Cheap

Otter Score

Fair

No chart data available for SCLX.

Trading Snapshot

Day Range: $540.02 – $550.45
52-Week Range: $2.62 – $27.00
Volume: $2.00B
Avg Volume: $2.54B
Shares Outstanding: 8.5M
Next Earnings: Nov 18, 2026

Fundamentals Snapshot

Annual Revenue: $30M
Last Q Revenue: $8M
P/E Ratio: -0.1
P/S Ratio: 1.2x
EPS (TTM): $-64.87
Dividend Yield: 0.00%
Dilution (1yr): −0.4%

Why Investors Own SCLX

✓High-growth profile — revenue up -0.9% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SCILEX HOLDING CO

SCLX

Financial Trends

Revenue

$30M▼ −46.5% YoY

Gross Margin

49.7%▼ −29.5% YoY

Operating Income

−$272M▲ +226.5% YoY

Free Cash Flow

$4M▼ −80.4% YoY

Shares Outstanding

6.9M▼ −0.4% YoY

Net Cash

−$128M▼ −$93M YoY

StockOtter · stockotter.space

About SCILEX HOLDING CO

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

🦦